Ridaforolimus (Deforolimus, MK-8669)

別名：AP23573

製品コード：S1022 純度：97%

Ridaforolimus (Deforolimus, MK-8669, AP23573) is a selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. Phase 3.

Ridaforolimus (Deforolimus, MK-8669)化学構造

CAS No. 572924-54-0

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 41800	国内在庫あり
5mg	JPY 28000	国内在庫あり
10mg	JPY 39600	国内在庫あり
50mg	JPY 132600	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（157）

質量管理及び製品安全説明書

現在のバッチを見る： 純度：>97%

Ridaforolimus (Deforolimus, MK-8669)関連製品

関連ターゲット	mTORC1 mTORC2	もっと見る
関連製品	Rapamycin (Sirolimus) Everolimus AZD8055 Torin 1 Sapanisertib (MLN0128) Temsirolimus Torkinib (PP242) Vistusertib (AZD2014) MHY1485 KU-0063794 Torin 2 OSI-027 WYE-354 WYE-125132 (WYE-132) 3BDO Palomid 529 (P529) Zotarolimus (ABT-578) Salidroside GDC-0349 WAY-600 Onatasertib (CC 223) XL388 WYE-687	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library PI3K/Akt Inhibitor Library Apoptosis Compound Library Cell Cycle compound library NF-κB Signaling Compound Library	もっと見る

シグナル伝達経路

mTORシグナル伝達経路

mTOR阻害剤の選択性比較

生物活性

製品説明

Targets

FKBP12 ^[6]	mTOR ^[1] (HT-1080 cells)
	0.2 nM

In Vitro
In vitro	Treatment of HT-1080 cells with Deforolimus induces a dose-dependent inhibition of phosphorylation of both S6 and 4E-BP1, with IC50 of 0.2 nM and 5.6 nM, respectively, and leads to a decrease in cell size, an increase in the proportion of cells in the G1 phase of the cell cycle, and inhibition of glucose uptake. Deforolimus displays significant antiproliferative activity a broad panel of cell lines with EC50 of 0.2-2.3 nM. Deforolimus potently and selectively inhibits VEGF production in a dose-dependent manner. ^[1] Deforolimus treatment significantly induces growth suppression in human NSCLC cell lines with IC30 values of 2.45-8.83 nM, with the exception of H157 with IC30 of >20 nM. Deforolimus treatment (2.8-5.9 nM) significantly dephosphorylates p70S6K^Thr389 in A549, H1703 and H157 cells, except H1666 that may express a resistant variant of mTORC1, and causes increased phosphorylation of pAKT^ser473 and pAKT^Thr308 in A549 and H1703 cells. Deforolimus in combination with the MEK inhibitors, CI-1040 or PD0325901 exhibits dose-dependent synergism in lung cancer cell lines, which is associated with the suppression of proliferation rather than enhancement of cell death, involving the inhibition of ribosomal biogenesis by 40% within 24 hours and a decreased polysome/monosome ratio. ^[2]
Kinase Assay	Cell based target inhibition
Kinase Assay	HT-1080 cells are treated with increasing concentrations of Deforolimus (0-100 nM) for 2 hours, prior to harvest. Cellular lysates are extracted in denaturing lysis buffer, resolved on SDS-PAGE and transferred to PVDF membranes. After blocking, membranes are incubated with primary antibodies for 1 hour, followed by appropriate HRPconjugated secondary antibodies for 1 hour at room temperature. Immunoreactive proteins are detected using enhanced chemiluminescence and autoradiography performed by exposure to X-ray film. IC50 is determined from the inhibition of levels of phosphorylated ribosomal protein S6 (p-S6) and 4E-BP1 (p-4E-BP1).
細胞実験	細胞株	Colo205, H1755, H1395, H1666, A549, H157, and H1703 cells
	濃度	Dissolved in ethanol, final concentrations ~ 1 μM
	反応時間	72-120 hours
	実験の流れ	Cells are seeded at 2-3 × 10⁴/mL, and serial dilutions of Deforolimus are added after 2 hours, for at least three cell doublings (72-120 hours). Deforolimus effects are measured using the CellTiter 96 Aqueous nonradioactive cell proliferation assay and Sulforhodamine B assays. For Deforolimus, growth effects are described as IC30 because rapamycin and its derivatives do not significantly impede cell proliferation.

In Vivo
In Vivo	Administration of Deforolimus exerts significant antitumor effects in mice bearing PC-3 (prostate), HCT-116 (colon), MCF7 (breast), PANC-1 (pancreas) or A549 (lung) xenografts in a dose-dependent manner, and inhibits mTOR signaling in in SK-LMS-1 xenograft model associated with inhibition of tumor growth. ^[1]
動物実験	動物モデル	Male and female athymic NCr-nu mice with xenografts established by subcutaneous implantation of PC-3, A549, HCT-116, MCF7, PANC-1 and SK-LMS-1 tumors
	投与量	~10 mg/kg
	投与経路	Intraperitoneally

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT01431547	Completed	Solid Tumors	Merck Sharp & Dohme LLC	February 2012	Phase 1
NCT01431534	Terminated	Solid Tumors	Merck Sharp & Dohme LLC	January 30 2012	Phase 1
NCT01380184	Completed	Cancer Advanced	Merck Sharp & Dohme LLC	July 5 2011	Phase 1
NCT01295632	Completed	Advanced Cancer	Merck Sharp & Dohme LLC	February 2011	Phase 1
NCT01212627	Terminated	Non-Small Cell Lung Cancer	Angela Taber MD\|Rhode Island Hospital\|The Miriam Hospital\|Memorial Hospital of Rhode Island\|Roger Williams Medical Center\|Brown University	September 2010	Phase 1

参考
[1] Rivera VM, et al. Mol Cancer Ther, 2011, 10(6), 1059-1071. [2] Legrier ME, et al. Cancer Res, 2007, 67(23), 11300-11308. [3] Gayle SS, et al. Anticancer Agents Med Chem, 2012, 12(2), 151-162. [4] Squillace RM, et al. Int J Oncol, 2012, 41(2), 425-432. [5] Nicolas Floch, et al. Cancer Res . 2012 Sep 1;72(17):4483-93. [6] David A Guertin, David M Sabatini. Sci Signal . 2009 Apr 21;2(67):pe24. + 展開

参考

+ 展開

化学情報

分子量	990.21	化学式	C₅₃H₈₄NO₁₄P
CAS No.	572924-54-0	SDF	Download Ridaforolimus (Deforolimus, MK-8669) SDFをダウンロードする
Smiles	CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OP(=O)(C)C)C)C)O)OC)C)C)C)OC
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ( (100.98 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):